small RNA binding exonuclease protection factor LaGenealiases: LARP3 · La · La/SSB
Q-omics provides the consensus-scored SSB profile across patient tissues and cancer cell-line models. SSB expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SSB is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SSB protein abundance shows 28,288 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where SSB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSB survival associations across molecular data types. SSB RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSB RNA expression–survival associations across cancer types. High SSB expression shows unfavorable associations in KIRP, ACC, LIHC, HNSC, LUAD and LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SSB RNA expression.
This table summarizes SSB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SSB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSB shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, STAD, COAD and BLCA. The HNSC box plot shows higher SSB RNA expression in tumor versus normal tissue (log2 FC = +1.250, t-test p < 0.001).
This table shows molecular features associated with SSB in patient tissues and cancer cell lines. In patient samples, SSB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SSB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
